ARHGAP11A and cancer: The Kaplan–Meier survival analyses demonstrated that HCC cancer patients with lower ARHGAP11A mRNA expression exhibited better prognosis compared with those patients with higher ARHGAP11A expression (Gehan-Breslow-Wilcoxon test, p = 0.0094, log-rank test, p = 0.059).